Watson Pharma Confirms Patent Challenge on Velcade
Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib. Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade ^ ® (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration, approved for the treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.